澳大新語 • 2021 UMAGAZINE 24 33 專題探討 • TOPIC INSIGHT of their research outcomes with industrial partners to promote the TCM sector in Macao. In May 2021, UM established a research and development centre for Chinese medicine and translational medicine at the Zhuhai UM Science & Technology Research Institute. The centre will play a key role in UM’s efforts to support technological innovations, the diversification of local industries, and the development of the Guangdong‑Hong Kong‑Macao Greater Bay Area into an international innovation and technology hub. Moreover, the SKL‑QRCM and the new TCM centre in Macao will work with pharmaceutical companies to meet the expectations of Macao SAR Chief Executive Ho Iat Seng. Following his instructions on research commercialisation, UM will give full play to the leading role of its state key laboratories, support the health industry and high‑tech industries with TCM as an initial focus, explore better mechanisms for industry‑academia collaboration, and gain vital experience for the commercialisation of other UM research outcomes. In 2015, Prof Chen’s team began to establish the quality standards for Ophiopogonis radix for Ph. Eur., and completed the project in 2019. In the beginning, the team established the standards for identification of the Chinese herbal medicine by comparing adulterated products with genuine ones using thin‑layer chromatography. They then used high‑performance liquid chromatography and ultraviolet–visible spectroscopy to determine the active ingredients of Ophiopogonis radix and to distinguish the good from the bad. They submitted a draft to the Ph. Eur. Commission, which then sought opinions from experts from EU countries. The commission included the final standard in the pharmacopoeia after revising the draft several times. In another push for Chinese medicine to Europe, Prof Chen is working with the commission to establish quality standards for Phyllanthi fructus. New Platforms for Industry‑Academia Collaboration According to Prof Wang, the SAR government has approved the establishment of a TCM research centre in Macao, which is a joint project among UM, China Resources, Guangzhou Pharmaceuticals, and the China Academy of Chinese Medical Sciences. This centre will join SKL‑QRCM and ICMS to study and produce Chinese medicine, improve the quality of patent drugs, and develop TCM products on a global scale. They will push forward the commercialisation 中華醫藥及轉化醫學研發中心揭牌 The inauguration ceremony for a research and development centre for Chinese medicine and translational medicine 掃二維碼 觀看訪談片段 Scan the QR code to watch the interview
RkJQdWJsaXNoZXIy MTQ1NDU2Ng==